Published: 3 September 2020
Publications
Recent approvals: New active ingredients or new indications
Published: 3 September 2020
Prescriber Update 41(3): 58–59
September 2020
For the period 16 April 2020 to 15 July 2020.
Recent approvals of medicines with new active ingredients
| Trade Name (active ingredient) | Dose form and strength(s) | Therapeutic area |
|---|---|---|
| Inovelon (rufinamide) | Tablet 100 mg 200 mg 400 mg |
Epilepsy |
| Nerlynx (neratinib) | Tablet 40 mg |
Breast cancer |
| Rozlytrek (entrectinib) | Capsule 100 mg 200 mg |
Neurotrophic tyrosine receptor kinase (NTRK) fusion-positive
locally advanced or metastatic solid tumours Non-small cell lung cancer |
| Takhzyro (lanadelumab) | Solution for injection 300 mg/2 mL |
Hereditary angioedema (C1-esterase-inhibitor deficiency or dysfunction) |
| UroFos (fosfomycin) | Oral granules 3 g |
Urinary tract infection |
| Zavicefta (avibactam; ceftazidime) | Powder for infusion 2000 mg/500 mg |
Infection |
Recent approvals of medicines with new indications
There were no recent approvals of medicines with new indications for the period 16 April 2020 to 15 July 2020.
- See the Medsafe website for more information about these medicines.
- Data sheets of currently marketed medicines are also available.
